Background: Proton pump inhibitors (PPIs) and histamine-2 receptor antagonists
| INTRODUCTION
Primary liver cancer is the fifth most common cancer in men and ninth in women in the world. 1 Recently, the incidence and mortality from liver cancer has increased markedly both in the UK 2 and USA. 3 The low estimates of 5 year relative survival of 15% in the USA, 4 and 8% in the UK, 5 highlight the importance of preventing liver cancer.
Proton pump inhibitors (PPIs) and histamine-2 receptor antagonists (H2RAs) are widely prescribed medications, used primarily for the treatment of peptic ulcers, dyspepsia, and gastro-oesophageal reflux disease (GERD). Despite their widespread use, there have been concerns about potential adverse effects of PPIs 6, 7 and H2RAs 8 potentially caused by a range of mechanisms including the reduced absorption of nutrients, 9 hypergastrinemia 10 and the overgrowth of bacteria (due to lower stomach acid levels). 8, 11 Many studies have investigated the effect of PPIs and H2RAs on the stomach, 12, 13 and particularly on gastric cancer risk. 14, 15 Recently, additional concerns have been raised about the effects that PPIs and H2RAs have upon the liver. A recent animal study found that PPIs promote progression of alcoholic liver disease, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis in mice 16 due to an overgrowth of bacteria. Likewise, in another animal study, PPI use was shown to promote liver tumors in rats. 17 Despite these findings, only one previous observational study has examined the association between PPI and H2RA use and the risk of primary liver cancer in humans. 18 That case-control study, which only investigated hepatocellular carcinoma (HCC), and not intrahepatic bile duct carcinoma (IBDC), observed a marked increase in risk of HCC with H2RA use but not PPI use. We therefore examined the association between use of PPIs and H2RAs and the risk of primary liver cancer using data from two independent UK datasets.
| MATERIALS AND METHODS

| Primary Care Clinical Informatics Unit
| Data source
The Primary Care Clinical Informatics Unit (PCCIU) database is an electronic primary care dataset from Scotland that captures approximately 15% of the Scottish population. 19 The PCCIU contains com- 
| Study design
We conducted a prospective cohort study among participants in the UK Biobank. Liver cancer patients were identified using cancer reg- 
| Exposure
Self-reported PPI and H2RA use was first ascertained from participants using a touchscreen questionnaire at baseline, and then verified during verbal interview with a UK Biobank nurse.
| Covariates
Covariates were determined from patient interview and touch screen at baseline. 
| Statistical analysis
The characteristics of cases and control were compared using descriptive statistics (for continuous variables) or frequencies and percentages (for categorical variables).
In PCCIU, we used conditional logistic regression to estimate odd ratios (OR) and 95% confidence intervals (95% CI) for the association between PPI/H2RA use and liver cancer risk. The matched design accounted for age, sex and GP practice, and adjustments were made for comorbidities (as described), obesity, aspirin and statins use. A separate complete case analysis was conducted additionally adjusted for smoking and alcohol.
Analyses were repeated by number of prescriptions, by DDDs and by type of PPIs. Similar analyses were conducted for H2RA use.
A sensitivity analysis was conducted adjusting for H2RAs and PPIs simultaneously. Additional sensitivity analyses were conducted removing prescriptions in the 2 years prior to index date (including only patients with 4 years of medical records), and in the 4 years prior to index date (including only patients with 6 years of medical records), to investigate the potential for reverse causation potentially due to gastrointestinal symptoms. A further sensitivity analysis was conducted adjusting for smoking and alcohol using multiple imputation with chained equations. 25 First, an imputation model was created using ordered logit models including age, gender, PPI, H2RA, obesity, comorbidity, statins and aspirin use, separately for cases and controls. Twenty-five imputations were conducted and results were combined using Rubin's rules. 26 The UK Biobank cohort was analysed using Cox regression with age as the underlying time scale (individuals were considered at risk from birth and under observation from age at baseline, left trun- 3 | RESULTS
| Primary Care Clinical Informatics Unit
Our nested case-control study in PCCIU included 434 cases of liver cancer and 2103 matched controls ( (Table 2 ).
In sensitivity analyses (Table 3) , the association with PPI use was moderately attenuated after introducing 2 year (fully adjusted OR 
| DISCUSSION
Using data from two large population-based studies which differed in design (case-control vs prospective cohort) and method of exposure ascertainment (self-report vs prescription records), we found a consistent association between PPI use and liver cancer risk. Conversely, there was little evidence of association with use of H2RAs.
PPI use was more strongly associated with the risk of IBDC than for HCC, and the association was not attenuated after adjustments for available confounders. However, the associations were slightly attenuated when controlling for potential reverse causation (using lags) and, using data from PCCIU, we found no evidence of a dose response based upon duration of use.
A previous case-control study in Taiwan in the findings of our study and the Taiwan study are unclear but could reflect differences in the underlying populations with respect to other liver cancer risk factors or genetic factors, differences in PPI prescribing patterns, or study specific differences (for instance they frequency matched controls to cases whereas we individually matched).
Our study has a number of strengths. We observed consistent findings for PPIs and liver cancer risk across two independent datasets. There was minimal risk of recall bias as PCCIU analyses were based upon GP prescription records whilst UK Biobank was a prospective cohort study in which medications were recorded at least 1 year prior to liver cancer onset. In both datasets, we adjusted for a wide range of confounders and, particularly, in UK Biobank, we had detailed information on lifestyle risk factors including smoking and alcohol. Also, data on number of prescriptions were available in PCCIU.
The main limitation is that we cannot rule out confounding by incomplete or unknown exposures. Although we adjusted for cirrhosis and liver disease, cirrhosis patients are commonly prescribed Study matched on age, gender and general practice and model contains obesity, comorbidities in exposure period (including diabetes, coronary heart disease, myocardial infarction, heart failure, peripheral vascular disease, cerebrovascular disease, cerebrovascular accident, chronic obstructive pulmonary disease, mental illness, liver disease, peptic ulcer disease) and other medication use in exposure period (statins, aspirin).
b Same model as "a" but alcohol and smoking added.
T | 61 data in UK Biobank. Finally, adherence to medications was unknown in either dataset, but this seems more likely to dilute associations.
The cause of the observed increased risk of liver cancer with PPIs use is unknown. If real, our findings are consistent with an experimental study which showed that PPIs can promote liver tumors in rats. 17 Various potentially harmful mechanisms of PPIs have been proposed. 9 In particular, long-term PPIs use can lead to hypergastrinemia which has been shown to have a carcinogenic effect, 30 particularly on liver cells. 31 Also PPIs reduce gastric acid secretion increasing the survival of various microbes in the stomach. 7, 32 The resulting bacterial overgrowth could greatly contribute to the transformation of primary bile acid in the intestine to secondary bile acid 33 and has been shown to impact upon the liver 34 exacerbating various liver diseases in mice. 16 A high level of secondary bile acid has been shown to cause toxic, inflammatory, and DNA damaging effects on liver cells and bile duct cells, leading to HCC 35 and cholangiocarcinoma. 36 The generally weaker associations observed for H2RAs could reflect the weaker acid suppression and the less marked effect on gastrin associated with these medications. 10 Alternatively, various features of the observed association do not support a causal interpretation including the lack of dose-response (the most marked association was seen for less than 6 prescriptions), the possibility of confounding by indication, and the possibility of reverse causation (suggested by the attenuation of associations when prescriptions in the period prior to diagnosis where removed). However, the widespread use of PPIs, and particularly their use without clear indication, 37 and the high mortality of liver cancer highlight the need for further research. Specifically, further studies should contain sufficiently long follow-up to investigate reverse causation, high quality liver cancer outcome data and detailed and complete information on liver cancer risk factors.
In conclusion, our study provides some evidence of an association between PPI use and the risk of liver cancer; however, this association requires confirmation in other studies due to the possibility of residual confounding and/or reverse causation.
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